Status:
COMPLETED
Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines
Lead Sponsor:
KU Leuven
Conditions:
Asthma
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements we...
Eligibility Criteria
Inclusion
- FEV1 \< 80% in the last 12 months
- use of high dose inhaled corticosteroids (ICS) in combination with other additional medication or continuous use of oral corticosteroids (OCS)
- at least 2 exacerbations in the last 12 months
- at least 300 blood eosinophils/µl once in the last 12 months and at the time of inclusion
- Anti-IL5 treatment prescribed by the physician
Exclusion
- Not completing all visits
Key Trial Info
Start Date :
September 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2019
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04412044
Start Date
September 1 2016
End Date
March 1 2019
Last Update
June 2 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.